Condition: ACS - Acute Coronary Syndrome · CYP2C19 Polymorphism · Sponsor: Zunyi Medical College
In Ease Asia clinical trials, P2Y12 inhibitor (ticagrelor or clopidogrel) monotherapy after 3-month dual antiplatelet therapy (DAPT) resulted in a lower incidence of clinically significant bleeding, without increasing risk of major adverse cardiac and cerebrovascular events, even if acute coronary syndrome (ACS) following complex percutaneous coronary intervention (PCI) when compared with standard DAPT. Although better understood "East Asian Paradox", finding the right CYP2C19 genotype-guided P2Y12 inhibitor selection to balance maintaining ischaemic prevention and less bleeding remains a topic in real-world clinical practice.
This description comes directly from the study's public registry record.
Cai De Jin, MD · 86+173-8576-9997 · jincaide1118@163.com
Yan Yan Jin, MD · 86+157-7229-0925 · jinyanyan850925@163.com
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Zunyi Medical University | Zunyi, Guizhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06283888